The interleukin-1 and interleukin-10 gene polymorphisms in primary sclerosing cholangitis: No associations with disease susceptibility/resistance

Journal of Hepatology

Volumn 32, Issue 6, 2000, Pages 882-886

  Donaldson, Peter T ^a   Norris, Suzanne ^c   Constantini, Patrizia K ^c   Bernal, Will ^c   Harrison, Phillip ^c   Williams, Roger ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c NONE

Author keywords

Autoimmunity; HLA DRB1*0301; IL 10 promoter; IL 1B; IL 1RN; Inflammatory bowel disease; Interleukin 1; Interleukin 10; Primary sclerosing cholangitis

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10;

ALLELE; ARTICLE; AUTOIMMUNE DISEASE; CHROMOSOME 2Q; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENTERITIS; GENETIC SUSCEPTIBILITY; GENOTYPE; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL;

EID: 0034043382     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80091-4     Document Type: Article

References (43)

1. hopf u, berg t, körber j, klein r, berg pa. autoimmune markers in primary sclerosing cholangitis. manns mp, chapman rw, stiehl a, wiesner r. primary sclerosing cholangitis. proceedings of the international falk workshop (part ii of liver week in freiburg 1997. 1998;46-51 kluwer academic publishers, london.
2. schrumpf e, fausa o, forre o, dobloug j, ritland s, thorsby e. hla antigens and immunoregulatory t cells associated with hepatobiliary disease. scand j gastroenterol. 17:1982;187-191.
3. chapman r, varghese z, gaul r, patel g, kokinon n, sherlock s. association of primary sclerosing cholangitis with hla-b8. gut. 24:1983;38-41.
4. shepherd h, selby w, chapman r, nolan d, barbatis c, mcgee j, jewell d. ulcerative colitis and persistent liver dysfunction. q j med. 52:1983;503-513.
5. donaldson pt, farrant jm, wilkinson ml, hayllar k, portmann bc, williams r. dual association of hla dr2 and dr3 with primary sclerosing cholangitis. hepatology. 13:1991;129-133.
6. farrant jm, doherty dg, donaldson pt, vaughan rw, hayllar km, welsh ki, et al. amino acid substitutions at position 38 of the dr beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. hepatology. 16:1992;390-395.
7. mehal w, lo y, wordsworth b, neuberger j, hubscher s, fleming k, et al. hla dr4 is a marker for rapid disease progression in primary sclerosing cholangitis. gastroenterology. 106:1994;160-167.
8. olerup o, olsson r, hultcrantz r, broome u. hla-dr and hla-dq are not markers for rapid disease progression in primary sclerosing cholangitis. gastroenterology. 108:1995;870-878.
9. donaldson pt, manns mp. immunogenetics of liver disease. bircher j, benhamou j-p, mcintyre n, rizzetto m, rhodes j. oxford textbook of clinical hepatology. 1:1999;173-188 oxford university press, oxford.
10. donaldson pt, constantini pk, underhill j, harrison pm. remodelling the hla associations with primary sclerosing cholangitis: novel association with phenylalanine at position 87 on dqβ-polypeptide. [abstract 964] hepatology. 28:1998;403a.
11. donaldson pt, norris s, underhill ja, constantini pk, harrison pm. hla associations in primary sclerosing cholangitis are present only in those patients with concurrent inflammatory bowel disease. [abstract 918] hepatology. 28:1998;392a.
12. bernal w, moloney m, underhill j, donaldson pt. association of tumour necrosis factor polymorphism with primary sclerosing cholangitis. j hepatol. 30:1999;237-241.
13. mansfield jc, holden h, tarlow jk, digiovine f, mcdowell tl, wilson ag, et al. novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. gastroenterology. 106:1994;637-642.
14. louis e, satsangi j, roussomoustakaki m, parkes m, fanning g, welsh k, et al. cytokine gene polymorphisms in inflammatory bowel disease. gut. 39:1996;705-710.
15. bioque g, crusius jba, koutroubakis i, bouma g, kostense pj, meuwissen sgm, et al. allelic polymorphism in il-1β and il-1 receptor antagonist (il-1ra) genes in inflammatory bowel disease. clin exp immunol. 102:1995;379-383.
16. heresbach d, alizadeh m, dabadie a, le berre n, colombel jf, yaouanq j, et al. significance of interleukin-1β and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. am j gatroenterol. 92:1997;1164-1169.
17. korman ks, crane a, wang h-y, digiovine fs, newman mg, pirk fw, et al. the intereukin-1 genotype as a severity factor in adult periodontal disease. j clin peridontal. 24:1997;72-77.
18. dinarello ca. biologic basis for interleukin-1 in disease. blood. 87:1996;2095-2147.
19. pociot f, molvig j, wogensen l, worsaae h, nerup j. a taql polymorphism in the human interleukin-1 beta (il-1 beta) gene correlates with il-1 beta secretion in vitro. eur j clin invest. 22:1992;396-402.
20. danis va, millington m, hyland vj, grennani d. cytokine production by normal human macrophages: inter-subject variation and relationship to an il-1 receptor antagonist (il-1ra) gene polymorphism. clin exp immunol. 99:1995;303-310.
21. santtila s, savinainen k, hurme m. presence of the il-1ra allele 2 (il1rn*2) is associated with enhanced il-1β production in vitro. scand j immunol. 47:1998;195-198.
22. hurme m, santtila s. il-1 receptor antagonist (il-1ra) plasma levels are co-ordinately regulated by both il-1ra and il-1b genes. eur j immunol. 28:1998;2598-2602.
23. kuhn r, lohler j, rennick d, rajewsky k, müller w. interleukin-10 deficient mice develop chronic enterocolitis. cell. 75:1993;263-274.
24. turner dm, williams dm, sankaran d, lazarus m, sinnott pj, hutchinson iv. an investigation of polymorphism in the interleukin-10 promoter. eur j immunogenet. 24:1997;1-8.
25. wilson a, symons j, mcdowell t, mcdevitt h, duff g. effects of a polymorphism in the human tumour necrosis factor a promoter on transcriptional activation. proc nat acad sci usa. 94:1997;3195-3199.
26. de waal malefyt r, abrams j, bennet b, figdor cg, de vries je. interleukin 10 (il-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of il-10 produced by monocytes. j exp med. 174:1991;1209-1220.
27. chapman r, arborgh b, rhodes j, summerfield j, dick r, scheur p, et al. primary sclerosing cholangitis: a review of its clinical features, cholangiography and hepatic histology. gut. 21:1980;870-877.
28. tarlow jk, blakemore ai, lennard a, solari r, hughes hn, steinkasserer a, et al. polymorphism in the human il-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. hum genet. 91:1993;403-404.
29. svejgaard a, ryder lp. hla and disease associations: detecting the strongest association. tissue antigens. 43:1994;18-27.
30. satsangi j, welsh ki, bunce m, julier c, farrant jm, bell ji, et al. contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. lancet. 347:1996;1212-1217.
31. toyoda h, wang s, yang h, redford a, magalong d, tyan d, et al. distinct associations of hla class ii genes in inflammatory bowel disease. gastroenterology. 104:1993;741-747.
32. yang h, plevy se, taylor k, tyan d, fischel-ghodsian n, mcelree c, et al. linkage of crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses. gut. 44:1999;519-526.
33. nakajima a, matsuhashi n, komada t, yazaki y, takazoe m, kimura a. hla-linked susceptibility and resistance genes in crohn's disease. gastroenterology. 109:1995;1462-1467.
34. heward j, gough scl. genetic susceptibility to the development of autoimmune disease. clin sci. 93:1997;479-491.
35. heresbach d, colombel f, danze pm, semana g. the hla drb1*0301-dqb1*0201 haplotype confers protection against inflammatory bowel disease. am j genet. 91:1996;1060.
36. saarinen a, broomé u, ligér a, olsson r, hultcrantz r, olerup o. ctla-4 gene polymorphism associated with primary sclerosing cholangitis (psc). [abstract p/c07/002] j hepatol. 28:((suppl 1)):1998;124.
37. agarwal k, jones dej, aithal g, daly a, bassendine mf, hudson m. ctla-4 gene polymorphism and susceptibility to inflammatory bowel disease. [abstract t165] gut. 44:1999;a42.
38. wang z, wang m, carr bi. the inhibitory effect of interleukin-1β on rat hepatocyte dna synthesis is mediated by nitric oxide. hepatology. 28:1998;430-435.
39. singh r, wang b, shirvairkar a, khan s, kamat s, schelling jr, et al. the il-1 receptor and rho directly associate to drive cell activation in inflammation. j clin invest. 103:1999;1561-1570.
40. simpson kj, lukacs nw, coletti l, strieter rm, kunkel sl. cytokines and the liver. 1997: j hepatol. 27:1997;1120-1132.
41. zappala f, grove j, watt fe, daly ak, day cp, bassendine mf, et al. no evidence for involvement of the interleukin-10 - 592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. j hepatol. 28:1998;820-823.
42. cookson s, constantini pk, clare m, underhill ja, bernal w, czaja aj, et al. the frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. hepatology. 30:1999;851-856.
43. gordon m, gleeson d, oppenheim e, di giovine fs, duff gw. new genetic association of an interleukin-1 beta gene variation with primary biliary cirrhosis. [abstract w68] gut. 37:1995;a17.